loadpatents
Patent applications and USPTO patent grants for TAO HEALTH LIFE PHARMA CO., LTD..The latest application filed is for "amylospheroid (aspd)-like structure and pharmaceutical composition".
Patent | Date |
---|---|
Amylospheroid (aspd)-like Structure And Pharmaceutical Composition App 20210214406 - HOSHI; Minako ;   et al. | 2021-07-15 |
Peptide For Inhibiting Binding Of Amylospheroids (aspd), And Evaluation And Screening Method App 20190145962 - HOSHI; Minako ;   et al. | 2019-05-16 |
Neurotoxic Target For Amylospheroid, Method And Material For Reducing The Neurotoxicity Of Amylospheroid, And Use Thereof App 20170327536 - HOSHI; Minako | 2017-11-16 |
Neurotoxic target for amylospheroid, method and material for reducing the neurotoxicity of amylospheroid, and use thereof Grant 9,751,912 - Hoshi September 5, 2 | 2017-09-05 |
Method for producing synthetic amylospheroid Grant 8,946,327 - Hoshi February 3, 2 | 2015-02-03 |
Neurotoxic Target For Amylospheroid, Method And Material For Reducing The Neurotoxicity Of Amylospheroid, And Use Thereof App 20130171069 - HOSHI; Minako | 2013-07-04 |
Antibody and use thereof Grant 8,445,649 - Hoshi , et al. May 21, 2 | 2013-05-21 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.